Polycythemia Vera (PV) (DBCOND0062825)

Identifiers

Synonyms
Polycythemia Vera / Polycythaemia vera / Primary polycythaemia / Vaquez's disease / Primary polycythemia / Polycythemia rubra vera / Polycythaemia rubra vera / Polycythemia vera (disorder) / Polycythemia vera (morphologic abnormality) / Secondary polycythemia / Polycythaemia NOS / Polycythaemia / Erythrocytosis (disorder) / Polycythemia

Associated Data

Indicated Drugs and Targets
DrugDescriptionTargets
Acetylsalicylic acid
A salicylate used to treat pain, fever, inflammation, migraines, and reducing the risk of major adverse cardiovascular events.
Busulfan
An alkylating agent used to treat chronic myelogenous leukemia.
Hydroxyurea
An antimetabolite used to treat sickle cell anemia crisis, resistant chronic myeloid leukemia, and Locally advanced squamous cell carcinomas of the head and neck (excluding the lip).
Mechlorethamine
An antineoplastic agent used to treat Hodgkin's disease, lymphosarcoma, and chronic myelocytic or lymphocytic leukemia.
Pacritinib
A kinase inhibitor used for the treatment of primary and secondary myelofibrosis in adult patients with significantly reduced platelet counts.
Ropeginterferon alfa-2b
A mono-pegylated type I interferon used to treat polycythemia vera.
Clinical Trials
IdentifierTitleDrug(s)PurposePhaseStatus
NCT05031897
Reduced-Intensity Conditioning for the Prevention of Treatment-Related Mortality in Patients Who Undergo a Hematopoietic Stem Cell TransplantNo drug interventionstreatment2recruiting
NCT05853458
Evaluation of HU-resistance in Adult Patients With Polycythemia Vera Who Meet PV-AIM Predictorstreatment4recruiting
NCT06378437
A Study of GLB-001 in Patients With Myeloid MalignanciesNo drug interventionstreatment1recruiting
NCT04629508
To Assess the Safety, Tolerability and Efficacy of Itacitinib Immediate Release Tablets in Participants With Primary or Secondary Myelofibrosis Who Have Received Prior Ruxolitinib and/or Fedratinib Monotherapy (LIMBER-213)treatment2completed
NCT06351631
A Study to Evaluate Safety and Efficacy of Bomedemstat (MK-3543-017)treatment3recruiting
NCT06506084
Observational Study on the Use of Ropeginterferon Alfa-2b in Polycythemia Vera (ROPEG-PV)Not AvailableNot Availablerecruiting
NCT05210790
A Phase 3 Study of Rusfertide in Patients With Polycythemia Veratreatment3active_not_recruiting
NCT04767802
PTG-300 in Patients With Polycythemia Vera and Elevated Hematocrittreatment2completed
NCT02912884
Treatment of Polycythaemia Vera and Essential Thrombocythaemia: Influence on the Clot StructureNo drug interventionsNot AvailableNot Availablecompleted
NCT05481151
A Study to Assess Efficacy, Safety, and Tolerability of P1101 in Adult Patients With PVtreatment3recruiting
NCT00890747
Sunitinib Malate in Treating HIV-Positive Patients With Cancer Receiving Antiretroviral Therapytreatment1completed
NCT00715247
Polycythemia Vera, Myelofibrosis and Essential Thrombocythemia: Identification of PV, MF & ET GenesNo drug interventionsNot AvailableNot Availablecompleted
NCT02897297
Myeloproliferative Neoplastic Diseases Observatory From BrestNo drug interventionsNot AvailableNot Availablerecruiting
NCT01998828
Safety and Efficacy of Momelotinib in Subjects With Polycythemia Vera or Essential Thrombocythemiatreatment2terminated
NCT06218628
Pacritinib w/ Talazoparib in Pts w/ Myeloproliferative Neoplasms Unresponsive to JAK2 Inhibitiontreatment1recruiting
NCT04644211
Ruxolitinib in Thrombocythemia and Polycythemia Veratreatment2recruiting
NCT03745378
Secondary Cancers in Myeloproliferative Neoplasms (MPN-K Study)No drug interventionsNot AvailableNot Availablecompleted
NCT04051307
Dual Vaccine Trial in Myeloproliferative NeoplasmsNo drug interventionstreatment1 / 2completed
NCT01038856
Trial of Erlotinib in Patients With JAK-2 V617F Positive Polycythemia Veratreatment2terminated
NCT00025415
Imatinib Mesylate in Treating Patients With Advanced Cancer and Liver Dysfunctiontreatment1completed
NCT01901432
A Two-part Study to Assess the Safety and Preliminary Efficacy of Givinostat in Patients With Polycythemia Veratreatment1 / 2completed
NCT01787552
A Phase Ib/II Dose-finding Study to Assess the Safety and Efficacy of LDE225 + INC424 in Patients With MFtreatment1 / 2completed
NCT00946270
Pomalidomide for Myelofibrosis Patientstreatment2completed
NCT00509899
Open Label Ruxolitinib (INCB018424) in Patients With Myelofibrosis and Post Polycythemia Vera/Essential Thrombocythemia Myelofibrosistreatment1 / 2completed
NCT03878199
Testing the Effect of Taking Ruxolitinib and CPX-351 in Combination for the Treatment of Advanced Phase Myeloproliferative Neoplasmstreatment1 / 2recruiting
NCT00666549
Research Tissue BankNo drug interventionsNot AvailableNot Availablecompleted
NCT03907436
The NUTRIENT Trial (NUTRitional Intervention Among myEloproliferative Neoplasms): Feasibility PhaseNo drug interventionstreatmentNot Availablecompleted
NCT02038036
Ruxolitinib Efficacy and Safety in Patients With HU Resistant or Intolerant Polycythemia Vera vs Best Available Therapy.treatment3completed
NCT05499013
Study to Assess SLN124 in Patients With Polycythemia Veratreatment1 / 2recruiting
NCT01384513
A Two-Step Approach to Reduced Intensity Bone Marrow Transplant for Patients With Hematological Malignanciestreatment2completed
NCT00397813
Fludarabine Phosphate and Total Body Irradiation Followed by a Donor Peripheral Stem Cell Transplant in Treating Patients With Myelodysplastic Syndromes or Myeloproliferative Disorderstreatment2completed
NCT00241241
Efficacy and Safety of Pegylated Interferon Alfa in Polycythemia Veratreatment2completed
NCT05558696
A Study of Bomedemstat (MK-3543) in Participants With Polycythemia Vera (MK-3543-004)treatment2active_not_recruiting
NCT06063486
Curcumin to Improve Inflammation and Symptoms in Patients With Clonal Cytopenia of Undetermined Significance, Low Risk Myelodysplastic Syndrome, and Myeloproliferative NeoplasmsNo drug interventionstreatment2recruiting
NCT03333486
Fludarabine Phosphate, Cyclophosphamide, Total Body Irradiation, and Donor Stem Cell Transplant in Treating Patients With Blood Cancertreatment2active_not_recruiting
NCT03003325
The Benefit/Risk Profile of AOP2014 in Low-risk Patients With PVtreatment2completed
NCT02493530
TGR-1202 + Ruxolitinib PMF PPV-MF PET-MF MDS/MPN Polycythemia Vera Resistant to Hydroxyureatreatment1completed
NCT03862157
Azacitidine, Venetoclax, and Pevonedistat in Treating Patients With Newly Diagnosed Acute Myeloid Leukemiatreatment1 / 2active_not_recruiting
NCT00430066
Effects of Imatinib Mesylate in Polycythemia Veratreatment2completed
NCT05123365
An Optimal Dose Finding Study of N-Acetylcysteine in Patients With Myeloproliferative Neoplasmstreatment1 / 2recruiting
NCT06290765
Efficacy and Safety of Ropeginterferon Alfa 2b (P1101) for Patients With Low-Risk Polycythemia Veratreatment4not_yet_recruiting
NCT00522574
A Safety Study of XL019 in Adults With Myelofibrosistreatment1terminated
NCT01134120
A Study in Myeloproliferative Disorderstreatment1completed
NCT01520220
Study of LY2784544 Testing Alternative Dosing in Participants With Myeloproliferative Neoplasmstreatment1completed
NCT02556931
Shorter Course Tacro After NMA, Related Donor PBSCT With High-dose Posttransplant Cy for Hard-to-Engraft Malignanciestreatment2completed
NCT05882773
Asian Myeloproliferative Neoplasm (MPN) RegistryNo drug interventionsNot AvailableNot Availablerecruiting
NCT06371573
Ultrasound Examination for Spleen Volume Evaluation in Myeloproliferative NeoplasmsNo drug interventionsNot AvailableNot Availablecompleted
NCT01529827
Fludarabine Phosphate, Melphalan, and Low-Dose Total-Body Irradiation Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignanciestreatment2completed
NCT05198960
AVAJAK: Apixaban/Rivaroxaban Versus Aspirin for Primary Prevention of Thrombo-embolic Complications in JAK2V617F-positive Myeloproliferative Neoplasmsprevention3recruiting
NCT00588991
Veliparib and Topotecan With or Without Carboplatin in Treating Patients With Relapsed or Refractory Acute Leukemia, High-Risk Myelodysplasia, or Aggressive Myeloproliferative Disorderstreatment1active_not_recruiting
NCT00227591
Lenalidomide and Prednisone in Treating Patients With Myelofibrosistreatment2completed
NCT01199562
Infection Prophylaxis and Management in Treating Cytomegalovirus (CMV) Infection in Patients With Hematologic Malignancies Previously Treated With Donor Stem Cell TransplantNot AvailableNot Availablecompleted
NCT00866762
A Study of the Efficacy of MK-0683 in Patients With Polycythaemia Vera and Essential Thrombocythaemiatreatment2unknown_status
NCT00433862
Molecular Changes and Biomarkers in Chronic Myeloproliferative DisordersNo drug interventionsNot AvailableNot Availablecompleted
NCT00445744
Cyclophosphamide and Busulfan Followed by Donor Stem Cell Transplant in Treating Patients With Myelofibrosis, Acute Myeloid Leukemia, or Myelodysplastic SyndrometreatmentNot Availablecompleted
NCT04057040
Hepcidin Mimetic in Patients With Polycythemia Vera (REVIVE)treatment2active_not_recruiting
NCT06093672
Study on Efficacy and Safety of Givinostat Versus Hydroxyurea in Patients With Polycythemia Veratreatment3recruiting
NCT02805868
Siltuximab in Treating Patients With Primary, Post-Polycythemia Vera, or Post-Essential Thrombocythemia Myelofibrosistreatment0withdrawn
NCT02292446
Expanded Treatment Protocol (ETP) of Ruxolitinib in Patients With Polycythemia Vera Who Were Hydroxyurea Resistant or Intolerant and for Whom no Treatment Alternatives Was Available.treatment3completed
NCT04896112
A Study of LNK01002 in Patients With Primary or Secondary Myelofibrosis,Polycythemia Vera or Acute Myeloid LeukemiaNo drug interventionstreatment1withdrawn
NCT03289910
Topotecan Hydrochloride and Carboplatin With or Without Veliparib in Treating Advanced Myeloproliferative Disorders and Acute Myeloid Leukemia or Chronic Myelomonocytic Leukemiatreatment2active_not_recruiting
NCT00745550
A Phase 1/2 Study of Oral SB1518 in Subjects With Chronic Idiopathic Myelofibrosistreatment1 / 2completed
NCT02760238
Myeloproliferative Neoplasms (MPNs) Patient RegistryNo drug interventionsNot AvailableNot Availablerecruiting
NCT00047190
Tipifarnib in Treating Patients With Myelofibrosis and Myeloid Metaplasiatreatment2completed
NCT00668421
CEP-701 (Lestaurtinib) in Myelofibrosistreatment1 / 2unknown_status
NCT01120821
Treatment of Polycythemia Vera With Gleevectreatment2completed
NCT06251102
Real-world Ruxolitinib Experience in PVNo drug interventionsNot AvailableNot Availablenot_yet_recruiting
NCT06134102
Clinical and Laboratory Characteristics of Polycythemia VeraNo drug interventionsNot AvailableNot Availablecompleted
NCT04116502
MITHRIDATE: Ruxolitinib Versus Hydroxycarbamide or Interferon as First Line Therapy in High Risk Polycythemia Veratreatment3recruiting
NCT02823184
Endoplasmic Reticulum Stress and Resistance to Treatments in Ph-negative Myeloproliferative NeoplasmsNo drug interventionsNot AvailableNot Availablecompleted
NCT00940784
Clopidogrel and Aspirin for the Treatment of Polycythemia Veratreatment2withdrawn
NCT04282187
Decitabine With Ruxolitinib, Fedratinib or Pacritinib for the Treatment of Accelerated/Blast Phase Myeloproliferative Neoplasmstreatment2recruiting
NCT00586651
Open-Label Study of Oral CEP-701 (Lestaurtinib) in Patients With Polycythemia Vera or Essential Thrombocytosistreatment2completed
NCT02218047
AOP2014 vs. BAT in Patients With Polycythemia Vera Who Previously Participated in the PROUD-PV Study.other3completed
NCT01499147
Fludarabine Based Conditioning for Allogeneic Transplantation for Advanced Hematologic MalignanciestreatmentNot Availablecompleted
NCT05853445
A Prospective, Non-interventional Study of JAKAVI® (Ruxolitinib) Treatment in Patients With Polycythemia VeraNo drug interventionsNot AvailableNot Availablecompleted
NCT03287245
A Study to Evaluate the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of Idasanutlin Monotherapy in Participants With Hydroxyurea-Resistant/Intolerant Polycythemia Veratreatment2terminated
NCT00357305
Vorinostat, Cytarabine, and Etoposide in Treating Patients With Relapsed and/or Refractory Acute Leukemia or Myelodysplastic Syndromes or Myeloproliferative Disorderstreatment1completed
NCT01949805
Pegylated Interferon Alpha-2b Versus Hydroxyurea in Polycythemia Veratreatment3completed
NCT00089011
Tacrolimus and Mycophenolate Mofetil in Preventing Graft-Versus-Host Disease in Patients Who Have Undergone Total-Body Irradiation With or Without Fludarabine Phosphate Followed by Donor Peripheral Blood Stem Cell Transplant for Hematologic Cancertreatment2completed
NCT00112593
Fludarabine and Total-Body Irradiation Followed By Donor Stem Cell Transplant and Cyclosporine and Mycophenolate Mofetil in Treating HIV-Positive Patients With or Without CancertreatmentNot Availablecompleted
NCT05269771
MAP to Provide Access to Ruxolitinib, for Patients With Polycythemia VeraNot AvailableNot Availableavailable
NCT00928707
Phase II Study of GIVINOSTAT (ITF2357) in Combination With Hydroxyurea in Polycythemia Veratreatment2completed
NCT01588015
Vaccine Therapy in Preventing Cytomegalovirus Infection in Patients With Hematological Malignancies Undergoing Donor Stem Cell TransplantNo drug interventionssupportive_care1completed
NCT03065400
PD-1 Inhibition in Advanced Myeloproliferative Neoplasmstreatment2completed
NCT02386800
CINC424A2X01B Rollover Protocoltreatment4recruiting
NCT00038675
Therapy of HES, PV, Atypical Chronic Myelocytic Leukemia (CML) or Chronic Myelomonocytic Leukemia (CMML), and Mastocytosis With Imatinib MesylatetreatmentNot Availablecompleted
NCT05870475
Pegylated Interferon α-2b in Combination With Ruxolitinib for Treating Hydroxyurea-resistant/Intolerant PVtreatment2recruiting
NCT03121599
18F-FLT (PET/CT) in Pediatrics With Myeloproliferative NeoplasmsNo drug interventionsdiagnosticNot Availableterminated
NCT01193699
Safety Study of Pegylated Interferon Alpha 2b to Treat Polycythemia Veratreatment1 / 2completed
NCT06361641
Functional and Phenotypic Characterization of Monocytes in Myeloproliferative SyndromesNo drug interventionsdiagnosticNot Availablerecruiting
NCT04262141
IMG-7289 in Patients With Essential Thrombocythemia (ET) or Polycythemia Vera (PV)treatment2active_not_recruiting
NCT01645124
Large-scale Trial Testing the Intensity of CYTOreductive Therapy in Polycythemia Vera (PV)treatment3terminated
NCT00039416
Imatinib Mesylate in Treating Patients With Myelofibrosistreatment2completed
NCT01831635
Myeloproliferative Neoplasms: an In-depth Case-control StudyNo drug interventionsNot AvailableNot Availablecompleted
NCT05566535
Changes in QoL and Symptoms in Patients With Polycythemia Vera Receiving Ruxo in a Routine Clinical PracticeNot AvailableNot Availableunknown_status
NCT01387763
A Study of Low Dose Interferon Alpha Versus Hydroxyurea in Treatment of Chronic Myeloid Neoplasmstreatment3completed
NCT04821063
Placebo-Corrected Effects of Therapeutic Dose (100 mg) and Supratherapeutic Dose (300 mg) of ITF2357 (Givinostat) and Moxifloxacin on QT/QTC Intervaltreatment1completed
NCT06033586
Study to Evaluate the Long-term Safety of Rusfertide (PTG-300) in Subjects With Polycythemia Veratreatment3enrolling_by_invitation
NCT01816022
Myeloproliferative Neoplasms and Bone StructureNo drug interventionsNot AvailableNot Availableunknown_status
NCT01970930
Tissue Banking Study - Polycythemia Vera or Essential Thrombocythemia (PV & ET) PatientsNo drug interventionsNot AvailableNot Availablecompleted
NCT05485948
A Study to Access Efficacy and Safety of P1101 in Chinese PV Patients Who Are Intolerant or Resistance to HUtreatment2active_not_recruiting
NCT02663648
Cell Cycle Regulatory Gene Study in Patients With Myeloproliferative DisordersNo drug interventionsNot AvailableNot Availablewithdrawn
NCT05993065
Hematocrit to Hemoglobin Ratio and Red Blood Cell Distribution Width in Polycythemia Vera and Secondary Erythrocytosis.No drug interventionsNot AvailableNot Availablerecruiting
NCT03669965
KRT-232 Compared to Ruxolitinib in Patients With Phlebotomy-Dependent Polycythemia Veratreatment2unknown_status
NCT02809274
Incidence of Iron Deficiency in Polycythemia Vera (PV) and Association With Disease FeaturesNo drug interventionsNot AvailableNot Availableunknown_status
NCT00052520
Biological Therapy in Treating Patients With Advanced Myelodysplastic Syndrome, Acute or Chronic Myeloid Leukemia, or Acute Lymphoblastic Leukemia Who Are Undergoing Stem Cell Transplantationtreatment1 / 2completed
NCT01243073
Open Label Study to Evaluate the Activity of Imetelstat in Patients With Essential Thrombocythemia or Polycythemia Veratreatment2completed
NCT01053494
Massage Therapy Given by Caregiver in Treating Quality of Life of Young Patients Undergoing Treatment for CancerNo drug interventionssupportive_careNot Availablecompleted
NCT05548062
Study to Identify and Describe Predictive Factors for Thromboembolic Events in Patients With High-risk Polycythemia VeraNo drug interventionsNot AvailableNot Availableactive_not_recruiting
NCT02407080
Open Label Study of Single Agent Oral RG7388 in Patients With Polycythemia Vera and Essential Thrombocythemiatreatment1completed
NCT00538980
Dasatinib in Polycythemia Veratreatment2terminated
NCT00595829
A Phase 1 Study of XL019 in Adults With Polycythemia Veratreatment1terminated
NCT00666289
Familial Myeloproliferative DisordersNo drug interventionsNot AvailableNot Availablecompleted
NCT01243944
Study of Efficacy and Safety in Polycythemia Vera Subjects Who Are Resistant to or Intolerant of Hydroxyurea: JAK Inhibitor INC424 (INCB018424) Tablets Versus Best Available Care: (The RESPONSE Trial)treatment3completed
NCT00665067
Correlative Biomarker Study in Patients With Myeloproliferative DisordersNo drug interventionsNot AvailableNot Availablecompleted
NCT02129101
Azacitidine and Sonidegib or Decitabine in Treating Patients With Myeloid Malignanciestreatment1completed
NCT01632904
Randomized Switch Study From Hydroxyurea to Ruxolitinib for RELIEF of Polycythemia Vera Symptoms: The Relief Studytreatment3completed
NCT02311569
Sympathicomimetic Agonist in Patients With Myeloproliferative Neoplasms With JAK2-mutationtreatment2completed
NCT00255346
Dasatinib as Therapy for Myeloproliferative Disorders (MPDs)treatment2completed
NCT01014546
Arsenic Trioxide With or Without Ascorbic Acid in Treating Patients With Myelofibrosistreatment1terminated
NCT02124746
Long-term Safety and Efficacy of Momelotinib in Subjects With Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis, Polycythemia Vera or Essential Thrombocythemiatreatment2completed
NCT01284712
Natural Killer Cells and Polycythemia Vera (Vaquez's Disease)No drug interventionsNot AvailableNot Availableunknown_status
NCT02893410
Drug Observance and Side Effects of Cytoreductive Drugs in PV and ET PatientsNo drug interventionsNot AvailableNot Availablecompleted
NCT01760655
Reduced-Intensity Conditioning Before Donor Stem Cell Transplant in Treating Patients With High-Risk Hematologic Malignanciestreatment2completed
NCT05074550
Safety Evaluation Study for Patients With Polycythemia VeraNo drug interventionstreatment1recruiting
NCT00381550
3-AP and Fludarabine in Treating Patients With Myeloproliferative Disorders, Chronic Myelomonocytic Leukemia, or Accelerated Phase or Blastic Phase Chronic Myelogenous Leukemiatreatment2completed
NCT01981850
A Phase 2 Study of RO7490677 In Participants With Myelofibrosistreatment2completed
NCT02523638
Study to Assess the Self-administration of AOP2014 Using a Pen, Developed for the Treatment of Polycythemia Vera Patientstreatment3completed
NCT03972943
CPAP in Treating Obstructive Sleep Apnea in Patients With Polycythemia Vera or Essential ThrombocythemiaNo drug interventionstreatment0terminated
NCT04821791
To Assess the Safety, Tolerability and Efficacy of Itacitinib Immediate Release Tablets in Participants With Primary or Secondary Myelofibrosis Who Have Received Prior Ruxolitinib and/or Fedratinib Monotherapy. (LIMBER-213)treatment2recruiting
NCT04745637
Managed Access Programs for INC424, RuxolitinibNot AvailableNot Availableavailable
NCT06002490
A Study to Evaluate P1101 in Japanese PV Patientstreatment3recruiting
NCT04655092
Extension Study of P1101 After Completion of Phase 2 Study in PV Patients or Phase 3 Study in ET Patientstreatment3recruiting
NCT05421104
Ruxolitinib for Polycythemia Vera in Patients Resistant to or Intolerant of Hydroxyurea.No drug interventionsNot AvailableNot Availablecompleted
NCT01816256
Screening for Asymptomatic Portal Vein Thrombosis and Portal Hypertension in Patients With Philadelphia Negative Myeloproliferative NeoplasmsNo drug interventionsscreeningNot Availablecompleted
NCT04182100
Efficacy and Safety of P1101 in Polycythemia Vera Patients for Whom the Standard of Treatment is Difficult to Applytreatment2completed
NCT06541249
MethoTRExATE in MyelOpRolifErative Neoplasms (TREATMORE) Trialtreatment2not_yet_recruiting
NCT04243122
Assessing Feasibility of Thromboprophylaxis With Apixaban in JAK2-positive Myeloproliferative Neoplasm Patientsprevention2completed
NCT02577926
The Ruxo-BEAT Trial in Patients With High-risk Polycythemia Vera or High-risk Essential Thrombocythemiatreatment2active_not_recruiting